Committee:

Eligible subjects will be randomised at the first visit of the treatment period to receive 1 of the dose levels of CSL312 (1, 3, 7, or 10 mg/kg) or placebo. Randomization will be 1:1:1:1:1 with stratification by 2 levels of PICC line (PICC gauge and PICC lumens [≤ 4 French and single lumen versus ≥ … ................
................